JMP reiterates Boston Scientific at strong buy

Boston Scientific Corp. was reiterated at a strong buy rating by JMP Securities analyst Robert C. Faulkner. Revenues were $894 million compared with JMP's estimate of $909 million and consensus of $903 million. While the analyst views the results of the quarter as a positive, the results confirm the market slowdown observed in St. Jude's pre-announcement. Shares of the Natick, Mass., medical device company were up 24 cents, or 1.11%, at $21.93 on volume of 19,454,700 shares versus the three-month running average of 10,828,800 shares. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.